Evogene
EVGN
16 hedge funds and large institutions have $527K invested in Evogene in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 15 → 16 (+1)
0.4% more ownership
Funds ownership: 5.92% → 6.32% (+0.4%)
30% less capital invested
Capital invested by funds: $752K → $527K (-$225K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$26.8K |
| 2 |
Jane Street
New York
|
+$18.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$15.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$3.62K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$118 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$29.7K |
| 2 |
JP Morgan Chase
New York
|
-$5.97K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.93K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$528 |
| 5 |
SAM
Synergy Asset Management
Vancouver,
Washington
|
-$61 |
EVGN Hedge Fund Activity: Q1 2025 in Review
16 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2025, worth a combined $527K — down 30% from $752K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new EVGN positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, adding an estimated $26.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $29.7K sold.
- 16 institutional investors held Evogene (EVGN) as of Q1 2025, up from 15 in Q4 2024.
- Funds reported $527K of Evogene stock for Q1 2025, down 30% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q1 2025 and 2 closed out, a net change of +1 holder.
- The largest Evogene buyer in Q1 2025 was Armistice Capital, an estimated $26.8K added.
- The largest Evogene seller in Q1 2025 was Citadel Advisors, an estimated $29.7K sold.
Based on aggregated 13F filings for Q1 2025.